Plexium focuses on targeted protein degraders to reinvent the way medicines are discovered.
The company's DELPhe platform, named for DNA-Encoded Library (DEL) phenotypic (Phe) screening, is a unique drug discovery engine designed to identify novel small molecules for multiple indications, including cancer and inflammatory disease indications.
- Swamy Vijayan, PhD
- #Plexium is looking to expand our team of drug hunters, with openings for positions such as Principal Scientist and… https://t.co/qDzlegrZss
- Our approach to TPD is highlighted in poster #1283 at this year's AACR meeting. We describe the discovery & unique… https://t.co/spM3wtUf7i
- Big news today – we closed a $35M financing w/ @Lux_Capital, Pivotal Bioventures, The Column Group, @DCVC and other… https://t.co/jtR1hty52Z